Harvard Apparatus Regenerative Technology, Inc.

Entered into securities purchase agreements with accredited investors for a $1.5 million private investment in public equity (PIPE) financing. The transaction closed on April 15, 2024. Received $0.5 million in convertible debt from Company’s CEO in February 2024. Holliston, MA, May 13, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today reported first quarter 2024 financial results. First Quarter 2024 Financial Results For the three months ended March 31, 2024, the Company reported a net loss of $2.0 million, ($0.15) per share, compared to a net loss of $3.0 million, ($0.24) per share, for the three months ended March 31, 2023. The $1.0 million quarter-over-quarter net loss decrease was primarily due to one-time share-based compensation expense of $1.5 million from the vesting of performance-based awards in the first quarter of 2023 offset by the addition of preclinical trial activities to increase our product pipeline and increased clinical trial activities in Q1 2024. Balance Sheet and Cash and Cash Equivalents At March 31, 2024, the Company had operating cash on-hand as of $0.3 million. The Company received $0.5 million in debt financing from a related party in February 2024. During the three months ended March 31, 2024, the Company used net cash in operations of $1.0 million and received $0.3 million from financing activities which consisted of advances received for a private placement transaction which closed in April 2024 for the issuance of common stock. About Harvard Apparatus Regenerative Technology, Inc. We are a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma or birth defects. Our technology is based on our proprietary cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. We believe that our technology represents a next-generation solution for restoring organ function because it allows the patient to regenerate their own organ, thus eliminating the need for human donor or animal transplants, the sacrifice of another of the patient’s own organs or permanent artificial implants. We conducted the world’s first successful regeneration of the esophagus in a patient with esophageal cancer in August 2017. This surgery was performed by Dr. Dennis Wigle, Chair of Thoracic Surgery at the Mayo Clinic. The results were published in the Journal of Thoracic Oncology Clinical and Research Reports in August 2021. The procedure demonstrated that our technology was able to successfully regenerate esophageal tissue, including the mucosal lining, to restore the integrity, continuity and functionality of the esophageal tube. HRGN has 13 issued U.S. patents, 2 issued in China, 1 issued in Japan, 2 issued in Europe and 2 orphan-drug designations which can provide seven years of market exclusivity once we won the market approval. For more information, please visit and connect with the Company on LinkedIn. Forward-Looking Statements Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements in this press release include, but are not limited to, statements relating to the capabilities and performance of our products and product candidates; development expectations and regulatory approval of any of the Company’s products, by the U.S. Food and Drug Administration, the European Medicines Agency or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; and success with respect to any collaborations, clinical trials and other development and commercialization efforts of the Company’s products, which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the Company’s inability to obtain needed funds in the immediate future; the Company's ability to obtain and maintain regulatory approval for its products; plus other factors described under the heading “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 or described in the Company’s other public filings. The Company’s results may also be affected by factors of which the Company is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based. Investor Relations Contacts Joseph Damasio Chief Financial Officer 774-233-7330 jdamasio@hregen.com HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value and share data) March 31, December 31, 2024 2023 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 272 $ 432 Accounts receivable 7 4 Inventory 44 50 Prepaid research and development 159 210 Prepaid expenses and other current assets 135 87 Total current assets 617 783 Property, plant and equipment, net 19 25 Right-of-use assets, net 21 48 Deferred financing costs 544 544 Long-term prepaid contracts 1,214 1,214 Total assets $ 2,415 $ 2,614 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 890 $ 445 Accrued and other current liabilities 528 475 Advance from private placement 301 — Convertible debt – related party 500 — Operating lease liability 21 48 Total current liabilities 2,240 968 Commitments and contingencies Stockholders’ equity: Common stock, par value $0.01 per share, 60,000,000 shares authorized; 13,947,324 issued and outstanding at March 31, 2024 and December 31, 2023, respectively 139 139 Additional paid-in capital 94,023 93,463 Accumulated deficit (93,986 ) (91,956 ) Accumulated other comprehensive loss (1 ) — Total stockholders’ equity 175 1,646 Total liabilities and stockholders’ equity $ 2,415 $ 2,614 HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (In thousands, except per share amounts) Three Months Ended March 31, 2024 2023 Product revenue $ 57 $ — Operating expenses: Cost of sales 12 — Research and development 840 509 Sales and marketing 115 — General and administrative 1,111 2,378 Total operating expenses 2,078 2,887 Operating loss (2,021 ) (2,887 ) Other expense, net: Other expense, net (9 ) (3 ) Net loss (2,030 ) (2,890 ) Preferred stock dividends — (80 ) Net loss attributable to common stockholders $ (2,030 ) $ (2,970 ) Basic and diluted net loss per share attributable to common stockholders $ (0.15 ) $ (0.24 ) Weighted average common shares outstanding, basic and diluted 13,947,324 12,206,036 Comprehensive loss: Net loss $ (2,030 ) $ (2,890 ) Foreign currency translation adjustments (1 ) — Comprehensive loss (2,031 ) (2,890 ) Less: Preferred stock dividends — (80 ) Comprehensive loss attributable to common stockholders $ (2,031 ) $ (2,970 )

Established a Research Collaboration with the McGowan Institute for Regenerative Medicine at the University of Pittsburgh to Study the Repair and Regeneration of the Colon following ColectomyEstablished a Collaboration with Hugh Taylor, MD, chair of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine to Repair and Regenerate the UterusActivated the second clinical trial site with the University of Michigan in August 2023 to expand the screening of patients.Received approval of an Orphan Disease Application for our lead product, the Cellspan Esophageal Implant by the European Medicines Agency (EMA for Esophageal Atresia). The EMA is the centralized regulatory agency for the review and approval of new medicines in the European Union.Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal DiseaseCompany’s subsidiary in Hong Kong launched its longevity product business in Asia, generating more than $100,000 in 2023 sales.Entered into securities purchase agreements with accredited investors for a $6 million private investment in public equity (PIPE) financing. The transaction closed on April 6, 2023. Holliston, MA, April 02, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today reported fourth quarter and full year 2023 financial results. Fourth Quarter 2023 Financial Results For the three months ended December 31, 2023, the Company reported a net loss of $1.8 million, ($0.13) per share, compared to a net loss of $1.6 million, ($0.14) per share, for the three months ended December 31, 2022. The $0.2 million year-over-year net loss increase was due primarily to share-based compensation expense of $0.3 million from the vesting of time-based awards in the fourth quarter of 2023 and increased headcount related costs of approximately $0.1 million offset by reduced pre-clinical activities. Full Year 2023 Financial Results For the year ended December 31, 2023, the Company reported a net loss of $9.0 million, ($0.67) per share, compared to a net loss of $6.3 million, ($0.55) per share, for the year ended December 31, 2022. The $2.8 million year-over-year net loss increase was due to clinical trial activities resulting in our activation of two sites, increased headcount costs and an increase in share-based compensation expense from the vesting of performance-based awards in 2023. Balance Sheet and Cash and Cash Equivalents At December 31, 2023, the Company had operating cash on-hand as of $0.4 million. The Company received $0.5 million in debt financing from a related party in February 2024. During the year ended December 31, 2023, the Company used net cash in operations of $6.9 million and received $6.1 million from financing activities and consisted of net proceeds received from a private placement transaction for the issuance of common stock and stock option exercises. About Harvard Apparatus Regenerative Technology, Inc. We are a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma or birth defects. Our technology is based on our proprietary cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. We believe that our technology represents a next-generation solution for restoring organ function because it allows the patient to regenerate their own organ, thus eliminating the need for human donor or animal transplants, the sacrifice of another of the patient’s own organs or permanent artificial implants. We conducted the world’s first successful regeneration of the esophagus in a patient with esophageal cancer in August 2017. This surgery was performed by Dr. Dennis Wigle, Chair of Thoracic Surgery at the Mayo Clinic. The results were published in the Journal of Thoracic Oncology Clinical and Research Reports in August 2021. The procedure demonstrated that our technology was able to successfully regenerate esophageal tissue, including the mucosal lining, to restore the integrity, continuity and functionality of the esophageal tube. HRGN has 13 issued U.S. patents, 2 issued in China, 1 issued in Japan, 2 issued in Europe and 2 orphan-drug designations which can provide seven years of market exclusivity once we won the market approval. For more information, please visit www.hregen.com and connect with the Company on LinkedIn. Forward-Looking Statements Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements in this press release include, but are not limited to, statements relating to the capabilities and performance of our products and product candidates; development expectations and regulatory approval of any of the Company’s products, by the U.S. Food and Drug Administration, the European Medicines Agency or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; and success with respect to any collaborations, clinical trials and other development and commercialization efforts of the Company’s products, which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the Company’s inability to obtain needed funds in the immediate future; the Company's ability to obtain and maintain regulatory approval for its products; plus other factors described under the heading “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 or described in the Company’s other public filings. The Company’s results may also be affected by factors of which the Company is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based. Investor Relations Contacts Joseph DamasioChief Financial Officer774-233-7330jdamasio@hregen.com HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. CONSOLIDATED BALANCE SHEETS(In thousands, except par value and share data) December 31, December 31, 2023 2022 ASSETS Current assets: Cash and cash equivalents $432 $1,241 Accounts receivable 4 — Inventory 50 — Prepaid research and development 210 274 Prepaid expenses and other current assets 87 79 Total current assets 783 1,594 Property, plant and equipment, net 25 49 Right-of-use assets, net 48 147 Deferred financing costs 544 610 Long-term prepaid contracts 1,214 — Total assets $2,614 $2,400 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable $445 $682 Accrued and other current liabilities 475 582 Operating lease liability, current 48 99 Total current liabilities 968 1,363 Operating lease liability, net of current portion — 48 Total liabilities 968 1,411 Commitments and contingencies Series E convertible preferred stock, par value $0.01 per share, 5,000 shares authorized; 0 and 4,180 shares issued and outstanding at December 31, 2023 and 2022, respectively — 4,180 Stockholders’ equity (deficit): Common stock, par value $0.01 per share, 60,000,000 shares authorized; 13,947,324 and 12,174,467 issued and outstanding at December 31, 2023 and 2022, respectively 139 122 Additional paid-in capital 93,463 79,698 Accumulated deficit (91,956) (83,011)Total stockholders’ equity (deficit) 1,646 (3,191)Total liabilities and stockholders’ equity (deficit) $2,614 $2,400 HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share amounts) Three Months Ended Year Ended December 31, December 31, 2023 2022 2023 2022 Product revenue $63 $— $103 $— Operating expenses: Cost of sales 11 — 24 — Research and development 648 744 3,062 1,742 Sales and marketing 96 — 294 — General and administrative 1,136 749 5,713 4,411 Total operating expenses 1,891 1,493 9,093 6,153 Operating loss (1,828) (1,493) (8,990) (6,153) Other income (expense), net: Sublease income — — — 87 Change in fair value of warrant liability — 2 — 2 Interest income 5 — 64 — Interest expense (3) (9) (14) (9)Other expense — 5 (5) — Total other income, net 2 (2) 45 80 Net loss (1,826) (1,495) (8,945) (6,073)Preferred stock dividends — (85) (77) (180)Net loss attributable to common stockholders $(1,826) $(1,580) $(9,022) $(6,253) Basic and diluted net loss per share $(0.13) $(0.14) $(0.67) $(0.55)Weighted average common shares, basic and diluted 13,925,333 11,615,642 13,455,666 11,349,610 HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands) Year ended December 31, 2023 2022 OPERATING ACTIVITIES Net loss $(8,945) $(6,073)Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: Share-based compensation expense 3,461 1,031 Depreciation 35 52 Amortization of operating right-of-use assets 99 22 Change in fair value of warrant liability — (2)Changes in operating assets and liabilities: Accounts receivable (4) — Inventory (50) — Prepaid research and development 64 (274)Prepaid expenses and other current assets (8) 216 Deferred financing costs 66 (610)Long-term prepaid contracts (1,214) — Accounts payable (237) 6 Operating lease liability (99) (22)Accrued and other current liabilities (107) 548 Net cash used in operating activities (6,939) (5,106) INVESTING ACTIVITIES Purchases of short-term investments (2,523) — Redemption of short-term investments 2,523 — Purchases of property, plant and equipment (11) (5)Net cash used in investing activities (11) (5) FINANCING ACTIVITIES Proceeds from issuance of common stock 5,992 5,060 Proceeds from exercise of stock options 149 — Net cash provided by financing activities 6,141 5,060 Net decrease in cash and cash equivalents (809) (51)Cash and cash equivalents at the beginning of the year 1,241 1,292 Cash and cash equivalents at the end of the year $432 $1,241 SUPPLEMENTAL INFORMATION Interest paid in cash $14 $9 Supplemental disclosure of non-cash activities: Settlement of contingency matter $— $(3,250)Settlement of due to Harvard Bioscience included in accrued and other current liabilities $— $(750)Issuance of Series E convertible preferred stock $— $4,000 Preferred stock dividends $77 $180 Increase of right-of-use asset and liability due to lease extension $— $63

This approach, along with the increasingly popular practice of cold exposure, is reshaping the pharma and wearable industry’s understanding of how to optimize physiological and mental well-being. Extreme athlete Wim Hof ​ has lauded the potential of these methods, emphasizing their profound impact on human health. Parasym, a pioneering neurotechnology company has introduced Nurosym, a wearable medical device designed to modulate the nervous system. Through targeted electrical signals delivered to the brain via the vagus nerve, Nurosym offers a novel approach to addressing a wide range of health conditions associated with autonomic nervous system imbalance. Backed by partnerships with respected institutions such as Harvard and UCL, Parasym says it has conducted extensive research demonstrating the efficacy of neuromodulation in managing chronic stress, fatigue, autoimmune disorders, migraines, anxiety, and more. The company says its auricular vagal neuromodulation therapy (AVNT), delivered through the Nurosym device, enhances the body's 'rest and digest' response, promoting feelings of calmness and safety while alleviating stress and fatigue. Clinical trials have shown that Nurosym can rapidly increase parasympathetic activity by an impressive 50% within just five minutes, offering a breakthrough in stress relief methods. In comparison, cold water immersion, often used for similar purposes, has been likened to the effect of roughly 100 ice baths, albeit with less predictability and requiring repeated exposure over time. googletag.cmd.push(function () { googletag.display('text-ad1'); }); Crucially, the company says neuromodulation differs from cold exposure by directly targeting specific therapeutic mechanisms in the body, as demonstrated in randomized double-blind placebo-controlled clinical trials. This approach yields significant and enduring benefits for health and performance, with bioelectric-induced improvements increasing over time due to a physiological memory effect. It says the benefits of AVNT extend beyond stress relief, encompassing enhanced parasympathetic activity, increased heart rate variability (HRV), and inflammation reduction. Clinical studies have shown a remarkable 78% decrease in inflammation among individuals with serious heart problems during a short hospital stay. The company believes Nurosym represents a groundbreaking advancement in bioelectric medicine, offering a CE-certified medical device that has already facilitated over 3,000,000 treatment sessions. With endorsements from Olympic athletes like Joel Naukkarinen and public figures like Bryan Johnson, Nurosym, the company says, is poised to revolutionize health and wellness, empowering individuals to optimize their well-being with cutting-edge wearable medical technology. Parasym's significant contributions to the field of medicine have garnered international recognition, earning them a place among the 'Top 20 Medical Device Companies To Watch.' The company's groundbreaking work has been featured and reviewed in prominent publications like The Guardian ​, solidifying their position at the forefront of healthcare innovation.